Aging & Vulnerability to Ischemia: Pathways & Rescue
Project Number3P01AG026467-05S1
Contact PI/Project LeaderSCHMIDT, ANN MARIE
Awardee OrganizationNEW YORK UNIVERSITY SCHOOL OF MEDICINE
Description
Abstract Text
DESCRIPTION (provided by applicant): Even after accounting for the major aging-associated diseases, the major factor underlying the enhanced propensity to cardiovascular diseases in human subjects is advancing age itself. Findings uncovered by this Program Project team highlight new concepts in the biology of aging: First, the level and activity of the polyol pathway enzyme aldose reductase (AR) is increased in heart, particularly in endothelial cells and cardiomyocytes. Multiple consequences ensue from upregulation of AR, including generation of diacylglycerol (DAG) and activation of Protein Kinase C (PKC); and production of 3 deoxyglucosone (3-DG) and methylglyoxal (MG), precursors of Advanced Glycation Endproducts (AGEs). Second, accumulation of AGEs and expression of Receptor for Advanced Glycation Endproducts (RAGE) is increased in healthy aged vs. young human and Fischer 344 rat hearts, especially in endothelial cells and cardiomyocytes. The interaction of AGE with RAGE is linked intimately to cellular and tissue perturbation and tissue injury. Our Program is built on the hypothesis that AR primes aged tissues for amplified cardiovascular dysfunction in the basal state. Upon superimposed I/R stress, at least in part via enhanced AGE generation and RAGE expression, increased biochemical and molecular signals amplify injury in the aged heart. We will dissect the influence and intersection of these pathways in aging and I/R stress, and determine the key signaling pathways that modulate expression of pro-inflammatory and prothrombotic genes in basal aging and I/R- stressed cardiovasculature.
This proposed Program will consist of three independent but highly integrated projects, led by a team of project leaders with a long history of collaboration in cardiovascular biology. Projects 1 & 2 will probe the role of AR pathway and RAGE in the intact heart, respectively. Project 3 will probe AR and RAGE in isolated EC and cardiomyocytes. These studies will address the questions: does basal modulation of AR and RAGE in aging prime the aged heart and, particularly, in endothelial cells and cardiomyocytes, for magnified injury upon I/R stress? Are these pathways, alone, or in combination, novel targets for cardiovascular protection in aging? The proposed Program Project will be supported by three cores: Administrative and Biostatistics; Animal Experimentation and Analysis; and Transgenic Mouse and Animal Management. These endeavors will shed light on mechanisms linking aging to enhanced vulnerability to I/R stress, and, potentially, uncover new therapeutic interventions to suppress I/R injury in the aging cardiovascular system.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
1,2-diacylglycerol3-deoxyglucosoneAccountingAddressAdvanced Glycosylation End ProductsAgingAldehyde ReductaseAnimal ExperimentationBiochemicalBiologyBiology of AgingBiometryCardiac MyocytesCardiovascular DiseasesCardiovascular systemCollaborationsDiglyceridesDiseaseElderlyEndothelial CellsFunctional disorderGenerationsGenesHeartHumanInflammatoryInjuryIschemiaLightLinkMolecularPathway interactionsProductionProtein Kinase CPyruvaldehydeRattusRecording of previous eventsRoleSignal PathwaySignal TransductionStressTissuesTransgenic AnimalsTransgenic MiceUp-Regulationagedenzyme pathwayhuman subjectnovelnovel therapeutic interventionpolyolprogramsreceptor for advanced glycation endproducts
No Sub Projects information available for 3P01AG026467-05S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3P01AG026467-05S1
Patents
No Patents information available for 3P01AG026467-05S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3P01AG026467-05S1
Clinical Studies
No Clinical Studies information available for 3P01AG026467-05S1
News and More
Related News Releases
No news release information available for 3P01AG026467-05S1
History
No Historical information available for 3P01AG026467-05S1
Similar Projects
No Similar Projects information available for 3P01AG026467-05S1